Please use this identifier to cite or link to this item:
https://hdl.handle.net/10316/108900
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Pereira, Patrícia A | - |
dc.contributor.author | Tomás, Joana F | - |
dc.contributor.author | Queiroz, João A | - |
dc.contributor.author | Figueiras, Ana R. | - |
dc.contributor.author | Sousa, Fani | - |
dc.date.accessioned | 2023-09-22T11:36:03Z | - |
dc.date.available | 2023-09-22T11:36:03Z | - |
dc.date.issued | 2016-01-28 | - |
dc.identifier.issn | 2045-2322 | pt |
dc.identifier.uri | https://hdl.handle.net/10316/108900 | - |
dc.description.abstract | MicroRNAs are arising as the next generation of diagnostic and therapeutic tools for gene silencing. Studies demonstrated that the miR-29 expression is decreased in Alzheimer's disease (AD) patients displaying high levels of human β-secretase (hBACE1). Recent advances toward an effective therapy for AD intend to employ miR-29 to suppress hBACE1 expression and subsequent Amyloid-β (Aβ) peptide. However, delivery of mature miRNA has demonstrated modest efficacy in vitro; therefore, the preparation of highly pure and biologically active pre-miRNA arises as one of the most important challenges in the development of these therapeutic strategies. Recently, we described a new strategy based arginine-affinity chromatography to specifically purify the recombinant pre-miR-29b. Following this strategy, the purified pre-miR-29b was successfully encapsulated into polyplexes that were further delivered in cytoplasm. It was verified that Chitosan/pre-miR-29b and Polyethylenimine/pre-miR-29b systems efficiently delivered pre-miR-29b to N2a695 cells, thus reducing the hBACE1 protein expression (around 78% and 86%, respectively) and Aβ42 levels (approximately 44% and 47%, respectively). Furthermore, pre-miR-29b downregulates the hBACE1 mRNA expression in 80%. Overall, it was demonstrated that the recombinant pre-miR-29b using polyplexes allowed to decrease the hBACE1 and Aβ42 expression levels, improving the currently available methodologies of miRNA-based therapeutics. | pt |
dc.language.iso | eng | pt |
dc.publisher | Springer Nature | pt |
dc.rights | openAccess | pt |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | pt |
dc.subject.mesh | Alzheimer Disease | pt |
dc.subject.mesh | Amyloid Precursor Protein Secretases | pt |
dc.subject.mesh | Amyloid beta-Peptides | pt |
dc.subject.mesh | Aspartic Acid Endopeptidases | pt |
dc.subject.mesh | Cell Line, Tumor | pt |
dc.subject.mesh | Drug Compounding | pt |
dc.subject.mesh | Gene Expression | pt |
dc.subject.mesh | Gene Expression Regulation | pt |
dc.subject.mesh | Genetic Therapy | pt |
dc.subject.mesh | Humans | pt |
dc.subject.mesh | MicroRNAs | pt |
dc.subject.mesh | Neurons | pt |
dc.subject.mesh | RNA Interference | pt |
dc.subject.mesh | RNA Precursors | pt |
dc.subject.mesh | RNA, Messenger | pt |
dc.subject.mesh | Transfection | pt |
dc.title | Recombinant pre-miR-29b for Alzheimer´s disease therapeutics | pt |
dc.type | article | - |
degois.publication.firstPage | 19946 | pt |
degois.publication.issue | 1 | pt |
degois.publication.title | Scientific Reports | pt |
dc.peerreviewed | yes | pt |
dc.identifier.doi | 10.1038/srep19946 | pt |
degois.publication.volume | 6 | pt |
dc.date.embargo | 2016-01-28 | * |
uc.date.periodoEmbargo | 0 | pt |
item.grantfulltext | open | - |
item.cerifentitytype | Publications | - |
item.languageiso639-1 | en | - |
item.openairetype | article | - |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
item.fulltext | Com Texto completo | - |
crisitem.author.researchunit | CNC - Center for Neuroscience and Cell Biology | - |
crisitem.author.orcid | 0000-0001-8170-1113 | - |
Appears in Collections: | I&D CNC - Artigos em Revistas Internacionais |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
Recombinant-premiR29b-for-Alzheimers-disease-therapeuticsScientific-Reports.pdf | 2.73 MB | Adobe PDF | View/Open |
Page view(s)
59
checked on May 8, 2024
Download(s)
11
checked on May 8, 2024
Google ScholarTM
Check
Altmetric
Altmetric
This item is licensed under a Creative Commons License